Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Even though Eisai’s Halaven showed an unprecedented overall survival effect in a very tough-to-treat breast cancer population, the drug appears to have flopped in a head-to-head study against Xeloda in an earlier line of therapy. Nevertheless, Eisai vows to pursue a regulatory filing that would expand the drug’s label, as planned.
You may also be interested in...
When Opportunity Knocks: Eisai Turns To Business Development
Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer – with an emphasis on externally sourced innovation – that put aggressive business development front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise.
A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.
A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.